MIRA Pharmaceuticals (MIRA) Competitors

$1.02 -0.01 (-0.97%)

Closing price 04:00 PM Eastern

Extended Trading

$1.03 +0.01 (+1.47%)

As of 06:05 PM Eastern

MIRA vs. HUMA, PLX, TNXP, TKNO, and MENS

Should you be buying MIRA Pharmaceuticals stock or one of its competitors? The main competitors of MIRA Pharmaceuticals include Humacyte (HUMA), Protalix BioTherapeutics (PLX), Tonix Pharmaceuticals (TNXP), Alpha Teknova (TKNO), and Jyong Biotech (MENS). These companies are all part of the "pharmaceutical products" industry.

How does MIRA Pharmaceuticals compare to Humacyte?

MIRA Pharmaceuticals (NASDAQ:MIRA) and Humacyte (NASDAQ:HUMA) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, profitability, dividends, earnings, analyst recommendations, valuation and risk.

: Humacyte has a consensus price target of $7.71, indicating a potential upside of 755.34%. Given Humacyte's stronger consensus rating and higher possible upside, analysts clearly believe Humacyte is more favorable than MIRA Pharmaceuticals.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MIRA Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.00
Humacyte
1 Sell rating(s)

0 Hold rating(s)

7 Buy rating(s)

0 Strong Buy rating(s)
2.75
: In the previous week, Humacyte had 5 more articles in the media than MIRA Pharmaceuticals. MarketBeat recorded 5 mentions for Humacyte and 0 mentions for MIRA Pharmaceuticals. Humacyte's average media sentiment score of 0.46 beat MIRA Pharmaceuticals' score of 0.00 indicating that Humacyte is being referred to more favorably in the news media.
Company Overall Sentiment
MIRA Pharmaceuticals Neutral
Humacyte Neutral
: MIRA Pharmaceuticals has a beta of 1.48, suggesting that its share price is 48% more volatile than the S&P 500. Comparatively, Humacyte has a beta of 2.31, suggesting that its share price is 131% more volatile than the S&P 500.
: 35.2% of MIRA Pharmaceuticals shares are owned by institutional investors. Comparatively, 44.7% of Humacyte shares are owned by institutional investors. 6.7% of MIRA Pharmaceuticals shares are owned by company insiders. Comparatively, 5.1% of Humacyte shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
: MIRA Pharmaceuticals has a net margin of 0.00% compared to Humacyte's net margin of -1,998.87%. MIRA Pharmaceuticals' return on equity of -210.90% beat Humacyte's return on equity.
Company Net Margins Return on Equity Return on Assets
MIRA Pharmaceuticals N/A -210.90% -198.94%
Humacyte -1,998.87% -990.48% -74.79%
: MIRA Pharmaceuticals has higher earnings, but lower revenue than Humacyte. Humacyte is trading at a lower price-to-earnings ratio than MIRA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
MIRA Pharmaceuticals N/A N/A -$10.44M -$1.53 N/A
Humacyte $2.04M 98.16 -$40.83M -$0.20 N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MIRA Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Humacyte	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

Company	Overall Sentiment
MIRA Pharmaceuticals	Neutral
Humacyte	Neutral

Company	Net Margins	Return on Equity	Return on Assets
MIRA Pharmaceuticals	N/A	-210.90%	-198.94%
Humacyte	-1,998.87%	-990.48%	-74.79%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MIRA Pharmaceuticals	N/A	N/A	-$10.44M	-$1.53	N/A
Humacyte	$2.04M	98.16	-$40.83M	-$0.20	N/A

Summary

Humacyte beats MIRA Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

How does MIRA Pharmaceuticals compare to Protalix BioTherapeutics?

MIRA Pharmaceuticals (NASDAQ:MIRA) and Protalix BioTherapeutics (NYSE:PLX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, valuation, earnings, dividends, analyst recommendations and risk.

: Protalix BioTherapeutics has a consensus price target of $12.00, indicating a potential upside of 512.24%. Given Protalix BioTherapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Protalix BioTherapeutics is more favorable than MIRA Pharmaceuticals.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MIRA Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.00
Protalix BioTherapeutics
0 Sell rating(s)

0 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
3.00
: In the previous week, MIRA Pharmaceuticals' average media sentiment score of 0.00 equaled Protalix BioTherapeutics'average media sentiment score.
Company Overall Sentiment
MIRA Pharmaceuticals Neutral
Protalix BioTherapeutics Neutral
: MIRA Pharmaceuticals has a beta of 1.48, meaning that its stock price is 48% more volatile than the S&P 500. Comparatively, Protalix BioTherapeutics has a beta of -0.01, meaning that its stock price is 101% less volatile than the S&P 500.
: 35.2% of MIRA Pharmaceuticals shares are held by institutional investors. Comparatively, 16.5% of Protalix BioTherapeutics shares are held by institutional investors. 6.7% of MIRA Pharmaceuticals shares are held by company insiders. Comparatively, 6.5% of Protalix BioTherapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
: MIRA Pharmaceuticals has a net margin of 0.00% compared to Protalix BioTherapeutics' net margin of -21.03%. Protalix BioTherapeutics' return on equity of -30.89% beat MIRA Pharmaceuticals' return on equity.
Company Net Margins Return on Equity Return on Assets
MIRA Pharmaceuticals N/A -210.90% -198.94%
Protalix BioTherapeutics -21.03% -30.89% -11.74%
: Protalix BioTherapeutics has higher revenue and earnings than MIRA Pharmaceuticals. Protalix BioTherapeutics is trading at a lower price-to-earnings ratio than MIRA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
MIRA Pharmaceuticals N/A N/A -$10.44M -$1.53 N/A
Protalix BioTherapeutics $52.74M 2.99 $8.31M -$0.09 N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MIRA Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Protalix BioTherapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Company	Overall Sentiment
MIRA Pharmaceuticals	Neutral
Protalix BioTherapeutics	Neutral

Company	Net Margins	Return on Equity	Return on Assets
MIRA Pharmaceuticals	N/A	-210.90%	-198.94%
Protalix BioTherapeutics	-21.03%	-30.89%	-11.74%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MIRA Pharmaceuticals	N/A	N/A	-$10.44M	-$1.53	N/A
Protalix BioTherapeutics	$52.74M	2.99	$8.31M	-$0.09	N/A

Summary

Protalix BioTherapeutics beats MIRA Pharmaceuticals on 7 of the 12 factors compared between the two stocks.

How does MIRA Pharmaceuticals compare to Tonix Pharmaceuticals?

MIRA Pharmaceuticals (NASDAQ:MIRA) and Tonix Pharmaceuticals (NASDAQ:TNXP) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, valuation, earnings, dividends, analyst recommendations and risk.

: Tonix Pharmaceuticals has a consensus price target of $22.00, indicating a potential upside of 62.96%. Given Tonix Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Tonix Pharmaceuticals is more favorable than MIRA Pharmaceuticals.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MIRA Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.00
Tonix Pharmaceuticals
1 Sell rating(s)

0 Hold rating(s)

2 Buy rating(s)

0 Strong Buy rating(s)
2.33
: In the previous week, Tonix Pharmaceuticals had 7 more articles in the media than MIRA Pharmaceuticals. MarketBeat recorded 7 mentions for Tonix Pharmaceuticals and 0 mentions for MIRA Pharmaceuticals. Tonix Pharmaceuticals' average media sentiment score of 0.14 beat MIRA Pharmaceuticals' score of 0.00 indicating that Tonix Pharmaceuticals is being referred to more favorably in the news media.
Company Overall Sentiment
MIRA Pharmaceuticals Neutral
Tonix Pharmaceuticals Neutral
: MIRA Pharmaceuticals has a beta of 1.48, meaning that its stock price is 48% more volatile than the S&P 500. Comparatively, Tonix Pharmaceuticals has a beta of 1.68, meaning that its stock price is 68% more volatile than the S&P 500.
: 35.2% of MIRA Pharmaceuticals shares are held by institutional investors. Comparatively, 82.3% of Tonix Pharmaceuticals shares are held by institutional investors. 6.7% of MIRA Pharmaceuticals shares are held by company insiders. Comparatively, 2.0% of Tonix Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
: MIRA Pharmaceuticals has a net margin of 0.00% compared to Tonix Pharmaceuticals' net margin of -946.22%. Tonix Pharmaceuticals' return on equity of -60.15% beat MIRA Pharmaceuticals' return on equity.
Company Net Margins Return on Equity Return on Assets
MIRA Pharmaceuticals N/A -210.90% -198.94%
Tonix Pharmaceuticals -946.22% -60.15% -54.52%
: MIRA Pharmaceuticals has higher earnings, but lower revenue than Tonix Pharmaceuticals. Tonix Pharmaceuticals is trading at a lower price-to-earnings ratio than MIRA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
MIRA Pharmaceuticals N/A N/A -$10.44M -$1.53 N/A
Tonix Pharmaceuticals $13.11M 13.80 -$124.02M -$14.27 N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MIRA Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Tonix Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Company	Overall Sentiment
MIRA Pharmaceuticals	Neutral
Tonix Pharmaceuticals	Neutral

Company	Net Margins	Return on Equity	Return on Assets
MIRA Pharmaceuticals	N/A	-210.90%	-198.94%
Tonix Pharmaceuticals	-946.22%	-60.15%	-54.52%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MIRA Pharmaceuticals	N/A	N/A	-$10.44M	-$1.53	N/A
Tonix Pharmaceuticals	$13.11M	13.80	-$124.02M	-$14.27	N/A

Summary

Tonix Pharmaceuticals beats MIRA Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

How does MIRA Pharmaceuticals compare to Alpha Teknova?

Alpha Teknova (NASDAQ:TKNO) and MIRA Pharmaceuticals (NASDAQ:MIRA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, media sentiment, profitability, analyst recommendations, risk and valuation.

: 13.8% of Alpha Teknova shares are owned by institutional investors. Comparatively, 35.2% of MIRA Pharmaceuticals shares are owned by institutional investors. 12.5% of Alpha Teknova shares are owned by insiders. Comparatively, 6.7% of MIRA Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
: In the previous week, Alpha Teknova had 1 more articles in the media than MIRA Pharmaceuticals. MarketBeat recorded 1 mentions for Alpha Teknova and 0 mentions for MIRA Pharmaceuticals. Alpha Teknova's average media sentiment score of 0.00 equaled MIRA Pharmaceuticals'average media sentiment score.
Company Overall Sentiment
Alpha Teknova Neutral
MIRA Pharmaceuticals Neutral
: Alpha Teknova currently has a consensus price target of $8.00, indicating a potential upside of 113.90%. Given Alpha Teknova's stronger consensus rating and higher probable upside, research analysts clearly believe Alpha Teknova is more favorable than MIRA Pharmaceuticals.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Alpha Teknova
1 Sell rating(s)
1 Hold rating(s)

0 Buy rating(s)

1 Strong Buy rating(s)
2.33
MIRA Pharmaceuticals
1 Sell rating(s)

0 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.00
: MIRA Pharmaceuticals has lower revenue, but higher earnings than Alpha Teknova. Alpha Teknova is trading at a lower price-to-earnings ratio than MIRA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Alpha Teknova $40.52M 4.95 -$17.26M -$0.33 N/A
MIRA Pharmaceuticals N/A N/A -$10.44M -$1.53 N/A
: Alpha Teknova has a beta of 0.47, suggesting that its share price is 53% less volatile than the S&P 500. Comparatively, MIRA Pharmaceuticals has a beta of 1.48, suggesting that its share price is 48% more volatile than the S&P 500.
: MIRA Pharmaceuticals has a net margin of 0.00% compared to Alpha Teknova's net margin of -42.59%. Alpha Teknova's return on equity of -23.32% beat MIRA Pharmaceuticals' return on equity.
Company Net Margins Return on Equity Return on Assets
Alpha Teknova -42.59% -23.32% -15.85%
MIRA Pharmaceuticals N/A -210.90% -198.94%

Company	Overall Sentiment
Alpha Teknova	Neutral
MIRA Pharmaceuticals	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alpha Teknova	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33
MIRA Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alpha Teknova	$40.52M	4.95	-$17.26M	-$0.33	N/A
MIRA Pharmaceuticals	N/A	N/A	-$10.44M	-$1.53	N/A

Company	Net Margins	Return on Equity	Return on Assets
Alpha Teknova	-42.59%	-23.32%	-15.85%
MIRA Pharmaceuticals	N/A	-210.90%	-198.94%

Summary

Alpha Teknova beats MIRA Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does MIRA Pharmaceuticals compare to Jyong Biotech?

Jyong Biotech (NASDAQ:MENS) and MIRA Pharmaceuticals (NASDAQ:MIRA) are both small-cap pharmaceutical products companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, media sentiment, profitability, analyst recommendations, risk and valuation.

: In the previous week, Jyong Biotech had 2 more articles in the media than MIRA Pharmaceuticals. MarketBeat recorded 2 mentions for Jyong Biotech and 0 mentions for MIRA Pharmaceuticals. Jyong Biotech's average media sentiment score of 0.00 equaled MIRA Pharmaceuticals'average media sentiment score.
Company Overall Sentiment
Jyong Biotech Neutral
MIRA Pharmaceuticals Neutral
: 35.2% of MIRA Pharmaceuticals shares are owned by institutional investors. 6.7% of MIRA Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
: Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Jyong Biotech N/A N/A N/A N/A N/A
MIRA Pharmaceuticals N/A N/A -$10.44M -$1.53 N/A
: Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Jyong Biotech
1 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
MIRA Pharmaceuticals
1 Sell rating(s)

0 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.00
: Jyong Biotech's return on equity of 0.00% beat MIRA Pharmaceuticals' return on equity.
Company Net Margins Return on Equity Return on Assets
Jyong Biotech N/A N/A N/A
MIRA Pharmaceuticals N/A -210.90% -198.94%

Company	Overall Sentiment
Jyong Biotech	Neutral
MIRA Pharmaceuticals	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jyong Biotech	N/A	N/A	N/A	N/A	N/A
MIRA Pharmaceuticals	N/A	N/A	-$10.44M	-$1.53	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jyong Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
MIRA Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Company	Net Margins	Return on Equity	Return on Assets
Jyong Biotech	N/A	N/A	N/A
MIRA Pharmaceuticals	N/A	-210.90%	-198.94%

Summary

MIRA Pharmaceuticals beats Jyong Biotech on 4 of the 7 factors compared between the two stocks.

Get MIRA Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MIRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MIRA vs. The Competition

Export

Metric	MIRA Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$42.86M	$3.40B	$6.25B	$11.87B
Dividend Yield	N/A	2.20%	2.73%	5.21%
P/E Ratio	-0.67	38.85	29.04	28.48
Price / Sales	N/A	155.54	476.48	60.89
Price / Cash	N/A	57.88	27.62	36.52
Price / Book	4.08	7.03	9.67	6.67
Net Income	-$10.44M	$23.62M	$3.55B	$332.64M
7 Day Performance	0.99%	3.67%	1.70%	2.01%
1 Month Performance	-8.11%	7.17%	5.62%	9.19%
1 Year Performance	-12.82%	67.04%	34.42%	39.59%

MIRA Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MIRA MIRA Pharmaceuticals	0.7398 of 5 stars	$1.02 -1.0%	N/A	N/A	$42.86M	N/A	N/A	2
HUMA Humacyte	2.5873 of 5 stars	$0.78 -3.5%	$7.71 +891.6%	N/A	$172.73M	$2.04M	N/A	150	Upcoming Earnings Gap Up
PLX Protalix BioTherapeutics	2.1814 of 5 stars	$2.13 -1.6%	$12.00 +464.7%	N/A	$171.22M	$52.74M	N/A	200
TNXP Tonix Pharmaceuticals	3.5728 of 5 stars	$12.77 -0.5%	N/A	N/A	$170.73M	$13.11M	N/A	50	Upcoming Earnings Analyst Forecast
TKNO Alpha Teknova	2.0476 of 5 stars	$3.18 +1.1%	$8.00 +152.0%	N/A	$170.21M	$40.52M	N/A	240	Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MIRA) was last updated on 5/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MIRA Pharmaceuticals (MIRA) Competitors

MIRA vs. HUMA, PLX, TNXP, TKNO, and MENS

How does MIRA Pharmaceuticals compare to Humacyte?

Summary

How does MIRA Pharmaceuticals compare to Protalix BioTherapeutics?

Summary

How does MIRA Pharmaceuticals compare to Tonix Pharmaceuticals?

Summary

How does MIRA Pharmaceuticals compare to Alpha Teknova?

Summary

How does MIRA Pharmaceuticals compare to Jyong Biotech?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MIRA vs. The Competition

MIRA Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

MIRA Pharmaceuticals (MIRA) Competitors

MIRA vs. HUMA, PLX, TNXP, TKNO, and MENS

How does MIRA Pharmaceuticals compare to Humacyte?

Summary

How does MIRA Pharmaceuticals compare to Protalix BioTherapeutics?

Summary

How does MIRA Pharmaceuticals compare to Tonix Pharmaceuticals?

Summary

How does MIRA Pharmaceuticals compare to Alpha Teknova?

Summary

How does MIRA Pharmaceuticals compare to Jyong Biotech?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MIRA vs. The Competition

MIRA Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools